Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Liabilities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Total Liabilities for 7 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 26.74% to $3.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Dec 2025, up 26.74% year-over-year, with the annual reading at $3.0 billion for FY2025, 26.74% up from the prior year.
  • Total Liabilities hit $3.0 billion in Q4 2025 for BridgeBio Pharma, up from $2.9 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $3.0 billion in Q4 2025 to a low of $1.5 billion in Q1 2021.
  • Historically, Total Liabilities has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2022.
  • Biggest five-year swings in Total Liabilities: soared 215.32% in 2021 and later fell 1.28% in 2023.
  • Year by year, Total Liabilities stood at $1.9 billion in 2021, then decreased by 0.55% to $1.9 billion in 2022, then increased by 1.12% to $1.9 billion in 2023, then grew by 25.84% to $2.4 billion in 2024, then rose by 26.74% to $3.0 billion in 2025.
  • Business Quant data shows Total Liabilities for BBIO at $3.0 billion in Q4 2025, $2.9 billion in Q3 2025, and $2.9 billion in Q2 2025.